Roth Capital Predicts Reduced Earnings for Gain Therapeutics

Gain Therapeutics, Inc. (NASDAQ:GANX) – Equities research analysts at Roth Capital decreased their Q2 2025 earnings per share (EPS) estimates for Gain Therapeutics in a note issued to investors on Wednesday, May 14th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings per share of ($0.18) for the quarter, down from their previous forecast of ($0.17). The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.71) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.84) EPS.

GANX has been the subject of a number of other research reports. Chardan Capital reissued a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, March 28th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday, March 17th. Finally, Scotiabank began coverage on Gain Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $8.20.

Gain Therapeutics Trading Up 11.0%

Shares of Gain Therapeutics stock opened at $2.01 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $3.19. The stock has a 50 day moving average price of $1.94 and a two-hundred day moving average price of $2.01. The stock has a market capitalization of $59.15 million, a PE ratio of -1.83 and a beta of 0.17.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16).

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Kovitz Investment Group Partners LLC purchased a new position in shares of Gain Therapeutics during the first quarter valued at approximately $91,000. Dauntless Investment Group LLC purchased a new position in shares of Gain Therapeutics during the first quarter valued at approximately $240,000. Bridgeway Capital Management LLC purchased a new position in shares of Gain Therapeutics during the fourth quarter valued at approximately $65,000. Northern Trust Corp boosted its position in shares of Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after buying an additional 39,642 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Gain Therapeutics during the fourth quarter valued at approximately $198,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.